Shots:
- The US FDA has granted 510(k) clearance to FreedomEDGE infusion system to subcutaneously administer Rystiggo (rozanolixizumab-noli) in generalized myasthenia gravis (gMG) patients
- FreedomEDGE Infusion System enables efficient large-volume SC drug delivery, expanding from home use to clinic-based care to deliver life-changing therapies across various care settings
- The system supports SC drugs with varying viscosity, flow rate, & volume requirements, plus shows a 97% adherence rate & have 8 on-label SC drugs used across >30 countries
Ref: Businesswire | Image: KORU Medical Systems | Press Release
Related News: KORU Medical Systems Seeks FDA Clearance for FreedomEDGE System to Deliver Phesgo in HER2+ Breast Cancer Patients
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
